Stiksa 1985.

Methods	Setting: Sweden, hospital outpatient clinic Length of intervention period: 3 weeks Randomisation: yes, computer generated sequence Allocation concealment: yes Design: crossover, no washout Masking: none Excluded: not stated Withdrawals: stated Baseline characteristics: comparable Jadad score: 3
Participants	20 adults: 11M 9F Mean (SD) age: 56.4 (7) years Inclusion criteria: Asthmatics currently receiving inhaled BDP 200 mcg/d for 8 months or longer Exclusion criteria: Not stated
Interventions	1. BDP: 200 mcg 1puff 4xdaily (800 mcg/d) via MDI 2. BUD 200 mcg 2 puffs 2xdaily (800 mcg/d) via MDI+Inhalet spacer 3. BUD 200 mcg 4 puffs 1xdaily (800 mcg/d) via MDI+Inhalet spacer
Outcomes	Morning PEFR Evening PEFR Daytime breathlessness score Night‐time breathlessness score Sleeping difficulty due to asthma score Daily beta2 agonist use
Notes	Author confirmed randomisation method and use of allocation concealment 10 patients were receiving treatment with oral prednisolone at enrolment. Not stated if carryover effects were tested for.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	A ‐ Adequate